Artwork

Innhold levert av KPFA.org - KPFA 94.1 Berkeley, CA. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av KPFA.org - KPFA 94.1 Berkeley, CA eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Corona Calls for 09.03.2024 – Novavax; Mpox

39:24
 
Del
 

Manage episode 437947646 series 3464906
Innhold levert av KPFA.org - KPFA 94.1 Berkeley, CA. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av KPFA.org - KPFA 94.1 Berkeley, CA eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Discussed in this episode:

  • The FDA has approved the latest iteration of the Novavax vaccine. Here are the main differences with the MRNA vaccines (Moderna and Pfizer) that had new versions approved slightly earlier:
    • Novavax works by injecting COVID spike proteins into the body, rather than injecting MRNA molecules that tell the body’s cells to manufacture COVID spike proteins for a while. There is some evidence Novavax may carry less risk of side effects on re-vaccination, especially for people who’ve had negative side effects from MRNA vaccination.
    • Because Novavax takes longer to manufacture, this round is calibrated to target a slightly older subvariant of COVID (JN.1) than the MRNA vaccines (KP.2); both are close relatives of the currently dominant subvariant in the the US (KP.3.1.1).
    • After a Novavax booster, antibody production seems to last longer, which may mean protection against severe COVID lasts longer too. (However, antibody production after a Novavax booster also seems to ramp up slower).

  • The WHO has declared a Public Health Emergency of International Concern over mpox.
    • The declaration was driven by a surge of cases in the Democratic Republic of Congo and neighboring countries that appears to be driven by a new variant (Clade 1b).
    • The existing smallpox / mpox vaccine work well to stop the spread of mpox, but the international public health response hasn’t gotten the vaccine everywhere it’s needed.
    • To date, there are no confirmed cases of the new variant in the US, which got its 2022 outbreak under control with a relatively successful vaccination campaign targeting groups at high risk of exposure.

To send us a question in advance of next week’s show, write to: coronacalls@kpfa.org. Tune in live Monday mornings (or Tuesdays when Monday’s a holiday) at 7:30am Pacific at kpfa.org

Podcast music credit: Now Son by Podington Bear, licensed under a Attribution-NonCommercial 3.0 International License.

The post Corona Calls for 09.03.2024 – Novavax; Mpox appeared first on KPFA.

  continue reading

69 episoder

Artwork
iconDel
 
Manage episode 437947646 series 3464906
Innhold levert av KPFA.org - KPFA 94.1 Berkeley, CA. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av KPFA.org - KPFA 94.1 Berkeley, CA eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Discussed in this episode:

  • The FDA has approved the latest iteration of the Novavax vaccine. Here are the main differences with the MRNA vaccines (Moderna and Pfizer) that had new versions approved slightly earlier:
    • Novavax works by injecting COVID spike proteins into the body, rather than injecting MRNA molecules that tell the body’s cells to manufacture COVID spike proteins for a while. There is some evidence Novavax may carry less risk of side effects on re-vaccination, especially for people who’ve had negative side effects from MRNA vaccination.
    • Because Novavax takes longer to manufacture, this round is calibrated to target a slightly older subvariant of COVID (JN.1) than the MRNA vaccines (KP.2); both are close relatives of the currently dominant subvariant in the the US (KP.3.1.1).
    • After a Novavax booster, antibody production seems to last longer, which may mean protection against severe COVID lasts longer too. (However, antibody production after a Novavax booster also seems to ramp up slower).

  • The WHO has declared a Public Health Emergency of International Concern over mpox.
    • The declaration was driven by a surge of cases in the Democratic Republic of Congo and neighboring countries that appears to be driven by a new variant (Clade 1b).
    • The existing smallpox / mpox vaccine work well to stop the spread of mpox, but the international public health response hasn’t gotten the vaccine everywhere it’s needed.
    • To date, there are no confirmed cases of the new variant in the US, which got its 2022 outbreak under control with a relatively successful vaccination campaign targeting groups at high risk of exposure.

To send us a question in advance of next week’s show, write to: coronacalls@kpfa.org. Tune in live Monday mornings (or Tuesdays when Monday’s a holiday) at 7:30am Pacific at kpfa.org

Podcast music credit: Now Son by Podington Bear, licensed under a Attribution-NonCommercial 3.0 International License.

The post Corona Calls for 09.03.2024 – Novavax; Mpox appeared first on KPFA.

  continue reading

69 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett